The pan-JAK inhibitor LAS194046 reduces neutrophil activation from severe asthma and COPD patients in vitro

Autor: Javier Milara, Beatriz Ballester, Alfredo de Diego, Marta Calbet, Isabel Ramis, Montserrat Miralpeix, Julio Cortijo

Publikováno v: Scientific Reports, Vol 12, Iss 1, Pp 1-12 (2022)

Abstract Non-T2 severe asthma and chronic obstructive pulmonary disease (COPD) are airway chronic inflammatory disorders with a poor response to corticosteroids. LAS194046, a novel pan-Janus kinase (JAK) inhibitor, shows inhibitory effects on T2 alle

Externí odkaz: https://doaj.org/article/b88406e1f3b144f5ba19e15646f52920

In vitro anti-inflammatory effects of AZD8999, a novel bifunctional muscarinic acetylcholine receptor antagonist /β2-adrenoceptor agonist (MABA) compound in neutrophils from COPD patients.

Autor: Javier Milara, Sonia Contreras, Alfredo de Diego, Marta Calbet, Mònica Aparici, Esteban Morcillo, Montserrat Miralpeix, Julio Cortijo

Publikováno v: PLoS ONE, Vol 14, Iss 1, p e0210188 (2019)

Recent evidence indicates that AZD8999 (LAS190792), a novel muscarinic acetylcholine receptor antagonist and β2-adrenoceptor agonist (MABA) in development for chronic respiratory diseases, induces potent and sustained relaxant effects in human bronc

Externí odkaz: https://doaj.org/article/81bdef1e1cae445ab600cc01ba807577

The pan-JAK inhibitor LAS194046 reduces neutrophil activation from severe asthma and COPD patients in vitro

Autor: Javier Milara, Beatriz Ballester, Alfredo de Diego, Marta Calbet, Isabel Ramis, Montserrat Miralpeix, Julio Cortijo

Publikováno v: SCIENTIFIC REPORTS
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname

Non-T2 severe asthma and chronic obstructive pulmonary disease (COPD) are airway chronic inflammatory disorders with a poor response to corticosteroids. LAS194046, a novel pan-Janus kinase (JAK) inhibitor, shows inhibitory effects on T2 allergic lung

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8418016f888431e791f08763bff13f2
https://pubmed.ncbi.nlm.nih.gov/35332239

Discovery of a Novel Inhaled PI3Kδ Inhibitor for the Treatment of Respiratory Diseases

Autor: Montse Erra, Jordi Gràcia, Joan Taltavull, Lluís Pagès, Elena Calama, María Domínguez, J.F. Caturla, Sonia Espinosa, F.J. Bernal, M. Carrascal, Mónica Bravo, M. I. Maldonado, Begoña Hernández, M Sabate, Montserrat Miralpeix, Marta Calbet, Stephane Paris, Lehner, M. Mir

Publikováno v: Journal of Medicinal Chemistry. 61:9551-9567

Oral PI3Kδ inhibitors such as Idelalisib and Duvelisib have shown efficacy as anticancer agents and Idelalisib has been approved for the treatment of three B-cell cancers. However, Idelalisib has a black box warning on its product label regarding th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8eb77a673cefaa1d74c30859d39900e
https://doi.org/10.1021/acs.jmedchem.8b00873

PI3K, p38 and JAK/STAT signalling in bronchial tissue from patients with asthma following allergen challenge

Autor: Dave Singh, Anna Domènech, Isabel Ramis, Montserrat Miralpeix, Marta Calbet, Neus Prats, Thomas Southworth, Alan Bell, Sarah Mason

Publikováno v: Biomarker Research
Biomarker Research, Vol 6, Iss 1, Pp 1-8 (2018)
Southworth, T, Mason, S, Bell, A, Ramis, I, Calbet, M, Domenech, A, Prats, N, Miralpeix, M & Singh, D 2018, ' PI3K, p38 and JAK/STAT signalling in bronchial tissue from patients with asthma following allergen challenge. ', Biomarker Research, vol. 6, no. 14 . https://doi.org/10.1186/s40364-018-0128-9

BackgroundInhaled allergen challenges are often used to evaluate novel asthma treatments in early phase clinical trials. Current novel therapeutic targets in asthma include phosphoinositide 3-kinases (PI3K) delta and gamma, p38 mitogen-activated prot

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b0e9826db641f650a34bcd617956538
https://pubmed.ncbi.nlm.nih.gov/29651336